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Abstract
Racial differences in the pathophysiology of atherothrombosis are poorly understood. We
explored the function and transcriptome of platelets in healthy black (n = 70) and white (n = 84)
subjects. PAR4 thrombin receptor induced platelet aggregation and calcium mobilization were
significantly greater in black subjects. Numerous differentially expressed (DE) RNAs were
associated with both race and PAR4 reactivity, including phosphatidylcholine transfer protein
(PCTP), and platelets from blacks expressed higher levels of PC-TP protein. PC-TP inhibition or
depletion blocked activation of platelets or megakaryocytic cell lines through PAR4 but not
PAR1. MiR-376c levels were DE by race and PAR4 reactivity, and were inversely correlated with
PCTP mRNA levels, PC-TP protein levels and PAR4 reactivity. MiR-376c regulated expression of
PC-TP in human megakaryocytes. A disproportionately high number of miRNAs DE by race and
PAR4 reactivity, including miR-376c, are encoded in the DLK1-DIO3 locus, and were lower in
platelets from blacks. These results support PC-TP as a regulator of the racial difference in PAR4-
mediated platelet activation, indicate a genomic contribution to platelet function that differs by
race, and emphasize a need to consider race effects when developing anti-thrombotic drugs.
Myocardial infarction and other ischemic arterial diseases like stroke typically result from
an occlusive platelet thrombus formed at the site of a ruptured or eroded atherosclerotic
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tplaque1. Thrombin is an especially potent physiologic agonist mediating in vivo platelet
activation, and human platelets express two thrombin receptors, protease activated receptors
1 and 4, referred to as PAR1 and PAR42, both of which mediate thrombin signaling in
platelet activation. During thrombin-induced platelet activation these receptors couple to
specific G proteins, leading to activation of phospholipases and protein kinases, hydrolysis
of phosphoinositides and increased cytoplasmic calcium3. Numerous differences in platelet
activation have been characterized following stimulation of PAR1 or PAR44–7. For
example, compared to PAR1, PAR4 induces a more sustained rise in [Ca2+]I
7 and is
responsible for the majority of intracellular calcium flux. These observations suggest
different kinetics or signaling pathways through platelet PAR1 and PAR4.
There is reproducible variation in platelet reactivity among different individuals – a
variation that likely contributes to thrombotic risk. The inter-individual variation in platelet
reactivity is heritable8, and this heritability is greater in blacks than in whites9, but there is
limited understanding of the genetic mechanisms responsible for this variability. Race is an
independent predictor of survival in coronary heart disease even when demographic,
socioeconomic, and clinical factors are considered10,11 suggesting there are yet-to-be
identified factors accounting for this racial disparity. We hypothesized a difference in
platelet function may represent an important mechanism accounting for some of the racial
disparity in thrombotic risk. Human platelets offer a unique opportunity to assess the
functional genomics of a primary cell in a relatively non-invasive and high-throughput
manner because they can be obtained by sampling the peripheral blood. We designed the
Platelet RNA And eXpression-1 (PRAX1) study to identify novel mRNAs and miRNAs
responsible for inter-individual variation in platelet reactivity using a cohort of 154 black or
white healthy individuals. We discovered racial differences in platelet function and gene
expression patterns that appear to contribute to this variation.
Results
Platelets from blacks demonstrate enhanced aggregation through PAR4
We performed ex vivo platelet aggregation testing on 163 young, non-diabetic and generally
healthy subjects. After exclusion due to use of anti-platelet medication or abnormal
hematological parameters, we included 154 subjects for RNA profiling and analyses
(Supplementary Table 1). When comparing platelet function from the 70 blacks and 84
whites, we observed no racial difference in the average platelet maximal aggregation
response to arachidonic acid, ADP, anti-CD9 antibody, collagen-related peptide or the
PAR1 activation peptide (PAR1-AP), which activate platelets through the thromboxane,
P2Y1/P2Y12, FcγRIIa, glycoprotein VI and PAR1 signaling receptors, respectively (Fig.
1a). However, aggregation in response to PAR4-AP, which activates platelets through the
PAR4 thrombin receptor, was higher in platelets from blacks compared to white subjects
(3.8-fold higher at 50 μM PAR4-AP [P<0.0001] and 1.4-fold higher at 75 μM PAR4-AP [P
< 0.0001]) (Fig. 1a; Supplementary Table 2). Using an agonist response score (ARS) that
allowed precise differentiation among subjects with the same maximal aggregation (defined
in Methods), the racial difference in PAR4-mediated platelet aggregation was even stronger
(P=6.76×10−9). Race was the dominant determinant of the PAR4 ARS when we considered
the racial differences in age, gender, body mass index (BMI) and platelet count
(Supplementary Table 1) in a multiple linear regression analysis (P=5.15×10−8).
To address the possibility that PAR4-AP did not reflect the true thrombin response, we
performed a detailed dose-response study (4 blacks and 3 whites) for racial differences in
the platelet aggregation response to thrombin, the physiologic agonist of PAR4 and PAR1
(Supplementary Fig. 1a). When we restricted thrombin signaling to PAR4 by inhibiting
PAR1 with BMS-20026112, platelets from black subjects aggregated faster than platelets
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tfrom white subjects at low concentrations of thrombin (Supplementary Fig. 1b–e). We
observed no racial difference in maximal percent aggregation to high concentrations of
thrombin through PAR4 (Supplementary Fig. 1a–d). Guided by results of the detailed
thrombin dose-response study, we performed a replicate study with an additional 5 black
and 5 white subjects. At low doses of thrombin (0.6 nM – 1 nM) platelets from black
subjects again aggregated faster than white subjects in the absence of PAR1 signaling
(P=3.56×10−5) (Fig. 1b).
Principal components analysis applied to genome-wide genotyping data from PRAX1
subjects revealed two distinct and non-overlapping groups that accounted for the largest
variance. Superimposition of the self-identified race information onto the PCA results (Fig.
1c) indicated a 100% concordance. Taken together, these data indicate a racial difference
specific to PAR4 signaling in human platelets.
Platelet protein coding transcripts DE by PAR4 reactivity and race
We prepared highly purified, leukocyte-depleted platelets (LDPs) from the PRAX1 study
subjects by density centrifugation of citrated whole blood followed by immunodepletion of
CD45+ leukocytes13. We profiled LDP mRNA by the Human Gene 1.0 ST Array
(Affymetrix). Based on a probability density plot, we selected a threshold for expression
(Supplementary Fig. 2, left panel).
Among expressed transcripts reflecting more than 9000 commonly expressed annotated
human genes, we identified 113 as DE by PAR4 reactivity, of which 93 correlated positively
(Supplementary Table 3a) and 20 correlated negatively (Supplementary Table 3b), using a
False Discovery Rate (FDR) q-value cutoff of 0.2514. We found that 97 of 113 (86%) of the
PAR4 correlated transcripts were also DE between races, a much higher fraction than would
be expected from the background rate of 30% DE by race among all platelet expressed
transcripts (OR=14.08, 95% CI.8.23–25.65, P=2.58×10−34), or the 36% DE by race found
by Zhang et al15. We performed analyses to ensure that racially divergent SNVs occurring in
the probe sequences on the Affymetrix Human Gene 1.0 ST Array did not drive the
observed probe-set level (transcript/gene) correlations (Supplementary Fig. 3).
Phosphatidylcholine transfer protein (PC-TP) and PAR4 reactivity
Since some of the 97 transcripts that were DE by race and PAR4 reactivity would be
expected to be false positives, we performed Gene Ontology (GO) analysis utilizing the
Database for Annotation Visualization and Integrated Discovery (DAVID) (http://
david.abcc.ncifcrf.gov/home.jsp) as a guide for considering the most plausible true
associations. Using default settings and all assayed mRNAs as the reference, we found
mRNAs DE by PAR4 reactivity to be positively enriched in genes with phospholipid
transporter activity (P=8.0×10−3), serine/threonine kinases (P=4.4×10−2) and proteins with
pleckstrin homology (P=2.9×10−3). All of these functional categories are known to be
relevant to platelet physiology. The gene encoding PC-TP (also called StARD2)16, PCTP,
showed the strongest correlation with race (P=10−23; q=10−20) and with PAR4 reactivity
(P=3.4×10−8; q=3.5×10−4) (Supplementary Table 3a). This was intriguing because lipid
regulation is important for platelet function, and PC-TP is highly specific for binding
phosphatidylcholine (PC) and catalyzes its transfer between membranes in vitro16. Blacks
expressed PCTP mRNA approximately 4-fold higher than whites (Fig. 2a), and we
confirmed this result by qRT-PCR (Fig. 2b) using samples selected to represent the extremes
of the distribution as well as intermediate levels. The Spearman Rank correlation coefficient
between the microarray and PCR data was 0.8263, and is within the normal validation range
when comparing microarray and qRT-PCR data17. We also validated this racial difference
by western immunoblotting of platelet lysates from all 70 black and 84 white subjects (Fig.
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t2c & 2d). Finally, we found a significant correlation between the normalized PC-TP protein
levels and reactivity to PAR4-AP among the PRAX1 samples (r=0.249, P=0.002, Pearson
correlation).
Pctp has been knocked out in mice18, but we found that wild type mouse platelets express
little or no Pctp protein (Fig. 2e), consistent with mouse platelet RNA data from Rowley et
al19. Thus, we needed other approaches to test its function in human platelets. Compound
A1 (LDN-193,188), which has been identified as a small molecule inhibitor of the PC
transfer activity of PC-TP20, displaces PC from the lipid binding pocket and increases the
thermal stability of the protein21. Incubation of human platelets with this specific PC-TP
inhibitor prevented aggregation in response to PAR4-AP but not PAR1-AP (Fig. 2f).
Calcium mobilization is a critical signaling event upon platelet activation through PAR4.
The megakaryocytic cell line, Meg-01 mobilizes calcium in response to thrombin 22, and
similar to platelets, we observed the PAR4-mediated intracellular calcium concentration was
more sustained than was the PAR1 response. Knockdown of PC-TP using siRNA blunted
calcium release in response to PAR4-AP but not PAR1-AP (Fig. 2g–h). In addition,
compared to platelets from white subjects, platelets from black subjects showed greater
calcium mobilization in response to PAR4-AP (Fig. 2i). These data demonstrate a role for
PC-TP in PAR4-mediated calcium flux in platelets and are consistent with PC-TP mediated
racial differences in platelet aggregation.
The PCTP gene is targeted by miR-376c
MicroRNA (miRNA)-mediated mRNA degradation represents a potential mechanism for
altering mRNA levels23,24. Prior efforts at platelet miRNA profiling have been rather small
and lacked data for PAR-mediated platelet activation13,25,26. We profiled the 154 PRAX1
platelet samples for miRNA levels and identified 178 miRNAs as commonly expressed in
human platelets using threshold criteria similar to the approach used for mRNA
(Supplementary Fig. 2). We considered the common platelet miRNAs that are DE by race
and predicted to target mRNAs also DE by race and PAR4 reactivity. Figure 3a concisely
presents the patterns observed in our data: (i) PAR4 response is higher in blacks than whites
(Fig. 3a, upper heatmap), (ii) corresponding elevation in blacks of those mRNAs that
positively correlate with the PAR4 response (Fig. 3a, middle heatmap shows more yellow in
left half) and (iii) miRNAs negatively associated with PAR4 reactivity that show lower
expression in blacks (Fig. 3a, more blue in lower left heatmap). Figure 3b illustrates a
focused network of miRNA-mRNA pairs in which 1) both the miRNA and mRNA are DE
by race, 2) both the mRNA and miRNA correlate with PAR4-mediated platelet reactivity, 3)
the miRNA is predicted to target the mRNA, and 4) the miRNA and mRNA levels are
inversely correlated.
Our analysis predicted PCTP to be targeted by miR-376c (Fig. 3b), and miR-376c levels
significantly inversely correlated with PCTP mRNA levels, PC-TP protein levels, and PAR4
reactivity in the PRAX1 cohort (Table 1). Over-expression of miR-376c reduced PC-TP
protein expression in HCT cells (Fig. 4a) as well as the Meg-01 megakaryocytic cell line
(Fig. 4b), and reduced PCTP mRNA levels in Meg-01 cells and the HEL megakaryocyte
cell line (Fig. 4c). Additionally, inhibition of miR-376c caused PCTP mRNA levels to rise
(Fig. 4c). We then isolated CD34+ hematopoietic stem cells from human cord blood and
differentiated them into megakaryocytes and proplatelets (Fig. 4d–e). Transfection of
miR-376c LNA inhibitor into CD34+-derived CD61+ megakaryocytes increased PCTP
mRNA levels by more than 3-fold, while overexpression of the miR-376c precursor
decreased PCTP mRNA by 22% (Fig. 4f). The extent of miR-376c knockdown by the anti-
miR-376c LNA inhibitor and overexpression by the precursor is shown in Supplementary
Fig. 4. Transfection with the LNA inhibitor had no effect on the expression level of a
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tdifferent miR-376 family member, miR-376b or on other miRNAs located within the same
miRNA cluster, miR-410 and miR-495 (Supplementary Fig 4). Finally, reporter gene assays
demonstrated the direct action of miR-376c on the wild type PCTP 3′UTR but not a mutant
PCTP 3′UTR construct with a deleted miR-376c binding site (Fig. 4g).
The DLK1-DIO3 miRNA cluster is expressed higher in whites
MiR-376c is one of a set of miRNAs DE by race that appeared to be positively correlated
with one another (Fig. 3a, vertical blue and yellow swatches in the miRNA heatmap;
highlighted by the vertical red bar next to the miRNA heatmap). Indeed, expression analysis
revealed a significant correlation among 24 of the 178 common platelet miRNAs, and all 24
mapped to chromosome 14q32.2 (Fig. 5a). This locus is most commonly called the DLK1-
DIO3 genomic region and contains a large cluster of miRNA genes (Fig. 5b).
When we generated a composite expression score for the miRNAs from this locus for each
of the 154 subjects, race showed a strong association with expression (black vs. white
P=1.09×10−5). When we included age, gender, BMI and platelet count in a multiple linear
regression analysis, race remained the dominant determinant of the DLK1-DIO3 region
miRNA expression (P=0.000166, partial F statistic). As shown in Figure 5c, all commonly
expressed DLK1-DIO3 region mature miRNAs (n=24) were higher in whites than blacks.
Supplementary Table 4 lists the commonly expressed miRNAs DE by race and
Supplementary Table 5 lists the DLK1-DIO3 region miRNAs with mean values, variance
and p-values by race. We confirmed racial differences in miRNA expression by qRT-PCR
(Supplementary Fig. 5).
Discussion
The richness of the PRAX1 data set provided unique opportunities to establish miRNA-
mRNA-physiology relationships that led to a number of novel and unexpected results.
Several major findings emerged. First, compared to platelets from whites, platelets from
blacks showed greater platelet reactivity in response to activation through the PAR4
thrombin receptor. Since PAR4 is expressed in tissues other than platelets (e.g., heart, brain,
liver), these findings could be relevant for non-thrombotic diseases believed to show racial
differences. Second, the novel platelet protein, PC-TP, mediated PAR4-dependent calcium
mobilization and aggregation. Compared to platelets from whites, platelets from blacks
expressed higher levels of PC-TP and greater PAR4-dependent calcium mobilization and
aggregation through PC-TP. Third, miR-376c regulated expression of PC-TP in both
megakaryocytes and megakaryocytic cell lines. We also discovered a genomic module of
miRNAs and target mRNAs that strongly correlate with this racial difference in PAR4-
mediated platelet aggregation. Many of these miRNAs clustered in the DLK1-DIO3 region
and were expressed at higher levels in platelets from whites than blacks. These findings
should be considered in clinical trials involving anti-platelet therapies and on-going drug
development of inhibitors of protease activated receptors.
There is a paucity of literature considering racial differences in platelet function, and we are
not aware of work considering either thrombin receptors or associations between race and
the platelet transcriptome. A single small study reported that calcium mobilization varied by
race in patients with hypertension27, but it was unclear if this difference was due to race or
disease (hypertension) and the responsible molecular mechanism was not considered. We
found that platelets from blacks demonstrated significantly greater activation to PAR4-AP
than platelets from whites. Compared to thrombin, PAR activating peptides have the
advantage of discriminating between PAR1 and PAR4 and are amenable to the relatively
high-throughput screening needed in the PRAX1 study. Nevertheless, to address the
possibility that there could be an unusual interaction between race and PAR4-AP but not
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tbetween race and thrombin (i.e., that PAR4-AP in this study does not reflect the true
thrombin response), we performed two additional studies with different subjects to assess
thrombin-induced platelet aggregation after PAR1 inhibition. Both the thrombin-dose-
response study and replicate study showed racial differences mediated by thrombin-
activated PAR4. Although the data suggest a possible racial difference in thrombin-induced
platelet aggregation in the absence of the PAR1 inhibitor, this difference was less
pronounced than in the presence of the PAR1 inhibitor and a larger sample size would be
needed to clarify this possibility. Since the greater aggregation in platelets from blacks was
apparent only at the earliest time points and lowest thrombin concentrations, the racial
difference in PAR4 reactivity may be primarily kinetic. Additional studies are needed to
determine whether there is a racial difference in the kinetics of the response to thrombin
when both PAR1 and PAR4 are functional. The fact that we observed no racial difference
for other agonists strongly supports a relationship between race and PAR4-mediated platelet
aggregation, and not the effects of other crucial variables of the read-out such as integrin
αIIbβ3 levels or a plasma protein. The data using thrombin and washed platelets also
indicate 1) there is not an unknown plasma “cofactor” that differs by race affecting PAR4-
mediated platelet activation and 2) the results are not due to racial differences in an
undiscovered protease that activates PAR4 and not PAR1. Furthermore, we measured
plasma fibrinogen and VWF activity and neither differed by race. Moreover, we observed
this racial difference in PAR4-AP induced platelet aggregation in separate cohorts from
different cities (Houston and Philadelphia) with independent reagents, instrumentation, and
personnel.
A fundamental aspect of our conclusion pertains to race. We recruited black and white
subjects randomly throughout the duration of the study and there was no sequential
recruitment bias by race. Although self-identified race and ethnicity (SIRE) has been shown
to strongly correlate with selected genomic markers and ancient geographical ancestry,28–31
we validated the use of SIRE in PRAX1 using PCA, which provided an unbiased
examination of structure in the genotype data. American blacks are an admixed group32 and
African lineages have greater diversity; these facts are reflected in the greater spread within
that PCA-defined group. Although this strong relationship between SIRE and genetic
markers supported conclusions regarding a genetic effect on platelet function, it does not
preclude a contribution of socioeconomic or environmental factors to variation in PAR4
reactivity.
Genome-wide gene expression analysis showed more DE transcripts were positively
associated with PAR4 reactivity than were negatively associated. Such asymmetry has been
noted in other studies33. Perhaps the human platelet response through PAR4 evolved in such
a way as to promote blood clotting after trauma, thus providing a survival advantage; genetic
drift is another possible explanation. One hundred thirteen mRNAs (out of >9000 expressed
transcripts) were DE by both race and PAR4 reactivity. We pursued PCTP because of its
strong statistical associations and because of its biologic plausibility. PC-TP belongs to the
steroidogenic acute regulatory transfer protein-related transfer (START) domain
superfamily, which constitutes a functionally diverse group of proteins that share a unique
START domain for binding lipids34. PC-TP has been presumed to be expressed primarily in
the liver, kidneys, and testis. PC-TP protein was not known to be present or function in
platelets35, although PCTP mRNA was one of a number of platelet mRNAs whose
expression increased after hemodialysis in patients with chronic kidney disease36. Besides
PC transfer in vitro, PC-TP also regulates both insulin and glucose metabolism in mice and
human cell lines16,37,38, but the human in vivo function of PC-TP remains unclear. PC
comprises a major fraction of platelet phospholipids and multiple subcellular locations of PC
may exist39. PC is the classic substrate for phospholipase D, generating phosphatidic acid
that can be converted to the second messenger diacylglycerol40. PC can also be hydrolyzed
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tby phospholipase C to generate phosphatidylinositol 4,5-bidphosphate with subsequent
release of calcium from intracellular stores. The PC-TP inhibitor, compound A1, blocked
PAR4- but not PAR1-induced platelet aggregation, supporting of a role for PC-TP in platelet
function. While it has been reported that A1 inhibits the closely PC-TP-related proteins
StARD7 and StARD1021, it does so less effectively. Furthermore, PCTP mRNA was 7.9-
fold and 9.40 fold higher than STARD7 and STARD10 mRNA respectively, in platelets,
according to our microarray data. This suggests that the predominant effect of A1 treatment
on platelets was inhibition of PC-TP. The lack of PAR1 inhibition by A1 suggests PC-TP
impacts on a signaling event downstream of PAR4 engagement but upstream of pathways
substantively shared by PAR1 and PAR4. However, depleting PC-TP in megakaryocytic
cells via shRNA interference produced a functional effect on calcium mobilization that was
also PAR4- but not PAR1-dependent. These studies in two different experimental systems,
in addition to the racial difference seen in PAR4-mediation platelet calcium mobilization
(Fig. 2i) support a novel role for PC-TP mediation of intracellular calcium transients and in
the racial difference in PAR4-induced platelet activation. The serine-threonine kinase,
AKT3, was also differentially expressed by race and PAR4 activation, consistent with the
observation that Akt3−/− murine platelets lack responsiveness to thrombin but not to other
agonists41.
The DLK1-DIO3 region at the 14q32.2 locus is evolutionarily conserved and imprinted,
harboring DLK1 and MEG3, antisense RTL1, many small nucleolar RNAs (snoRNAs), long
intergenic RNAs (lincRNAs) (including MEG3) and the largest currently known cluster of
miRNAs in the human genome (reviewed in reference 42). The expression of some of the
DLK1-DIO3 miRNAs has been associated with murine stem cell pluripotency43, human
cancers42, and paternally inherited type 1 diabetes has been mapped to this region44. The
molecular mechanism for coordinate expression of human DLK1-DIO3 region miRNAs is
unclear, although data in mice supports processing of a single large transcript containing
mature miRNAs 3′ of the snoRNAs cluster45, and independent genes/transcripts and
promoters 5′ of snoRNAs cluster46. We note that our data do not exclude a role for
lincRNAs or snoRNAs in regulating PAR-dependent gene expression.
Our data demonstrate the miRNAs in this region are expressed at higher levels in platelets
from white subjects than black subjects, and it will be important to assess other tissues and
the other RNAs encoded in this region for this racial difference. MiR-376c, which resides
within the DLK1-DIO3 region, was DE by race and PAR4-induced platelet reactivity and
was predicted to target the 3′UTR of PCTP. As might be expected if miR-376c targeted
PCTP and resulted in mRNA degradation, miR-376c levels were inversely correlated with
PC-TP mRNA and protein, and weakly correlated with PAR4-induced platelet aggregation.
A series of overexpression, inhibition and binding site mutation studies in a variety of cell
types, including primary cultured human megakaryocytes demonstrated direct perturbation
of PCTP expression by miR-376c. Fig. 5d summarizes the proposed relationships identified
in this study, emphasizing the race effect on RNAs, leading to racial differences in platelet
PAR4 reactivity. Although the there is a strong correlation between the platelet and
megakaryocyte transcriptomes47, racial differences in platelet RNAs cannot be assumed to
reflect differences that occurred in the megakaryocytes. Addressing this possibility would
require a racially diverse source of progenitor cells. Nevertheless, transcriptomic and
bioinformatic analyses of platelet RNA can guide experiments in cells to permit insights into
relevant gene regulation in megakaryocytes.
There are clinical consequences to our findings, particularly in an era where personalized
medicine has been advanced as a strategy to improve patient outcomes. First, awareness and
understanding of differences by which platelets are activated in blacks and whites is
expected to aid in our ability to optimally treat these populations following myocardial
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tinfarction and stroke. Although the issue of race serving as a proxy for genetics in medical
practice and research is controversial48, our results suggest SIRE may have value in
assessing hemostasis-thrombosis risk in some populations. Anti-platelet therapy is a
mainstay of managing coronary heart disease. However, there has been a notable absence or,
at best poor representation of blacks in clinical trials of anti-platelet therapies and in
genome-wide association studies of atherothrombotic phenotypes. Unfortunately, neither
cardiovascular trials with PAR1 inhibitors nor trials listed at clinicaltrials.gov allow
assessment of racial effects in clinical outcomes, and it is unknown whether the racial
difference in platelet reactivity impacts the benefits and risks of these treatments. The PAR1
inhibitor vorapaxar is effective at preventing secondary atherothrombotic events, but at a
cost of increased bleeding49–51 and other novel inhibitors of PAR1 and PAR4 are currently
in clinical development52. In the presence of vorapaxar, PAR4 is the only means by which
thrombin can activate platelets. Thus, it is critical to know whether selection and dosing of
such agents should be adjusted by race to maximize benefit and avoid toxicity. Our findings
call for greater access to clinical trial data to address the effect of race on anti-platelet
therapies. In addition, the racial differences identified in the DLK1-DIO3 region miRNA
expression may be present in other tissues, and more large scale RNA studies can address
this question. Lastly, it will be of interest to know whether PC-TP inhibition might prove
useful as an anti-thrombotic strategy, especially in disorders of altered glucose and insulin
metabolism.
Online Methods
Subjects
The Institutional Review Boards of Thomas Jefferson University and Baylor College of
Medicine approved the Platelet RNA And eXpression-1 (PRAX1) study, and we obtained
informed consent from all volunteers. Only healthy, non-diabetic subjects who self-
identified their race as white or black, using no anti-platelet medications were eligible for
this study. We recruited black and white subjects randomly throughout the duration of the
study. We recruited donors from 2010–2011 in Houston, TX, and in 2013 in Philadelphia,
PA, and collected blood as previously described53.
Platelet function assessment
Houston studies. We obtained a complete blood count and mean platelet volume using an
ABX Micros 60 CS (Horiba ABX, Irvine, CA, USA). Using light transmission
aggregometry, we measured maximal percent aggregation and slope of aggregation at 10
min in platelet rich plasma (PRP) treated with: 0.5 mg ml−1 arachidonic acid, 4 μM ADP,
500, 750 and 2000 ng ml−1anti-CD9, 10 and 20 ng ml−1 collagen-related peptide (CRP),1
μM and 2 μM PAR1 activating peptide (PAR1-AP), and 50 μM and 75 μM PAR4 activating
peptide (PAR4-AP). Philadelphia studies. We used light transmission aggregometry of
washed platelets to assess thrombin-induced platelet aggregation without or with a 2 min
pre-incubation with 20 μM BMS-200261 (BMS, PAR1-specific antagonist)12. We observed
a difference in the efficacy of the PAR1 inhibitor between the pilot and replicate studies, but
confirmed validation of inhibitor activity for both studies (Fig 1b inset and Supplementary
Fig 1e). For assessment of calcium mobilization, we re-calcified platelets to a final
concentration of 1 mM followed by pre-incubation with Fluo-4 AM for 10 min. We then
stimulated platelets with PAR4-AP and measured calcium mobilization using the Accuri C6
flow cytometer54. We minimized, in both Houston and Philadelphia, technical variation by
use of the same highly-trained technicians, same lots of reagents and same instruments
throughout the duration of the study. Because we used multiple concentrations to activate
PAR1 and PAR4 to induce platelet aggregation, we developed an integrated score that
combined these values to determine a single index that represented each individual’s agonist
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tresponse. This score correlated strongly with standard assessment of maximal percent
aggregation, but inclusion of slope (which was a minor contributor to the overall score, and
highly related to maximal aggregation) allowed distinction among platelets with the same
maximal aggregation value. This score was highly reproducible in 10 subjects studied
weekly for three or four weeks.
Plasma assays
We measured plasma fibrinogen level and von Willebrand factor activity on an ACL TOP
500 (Instrumentation Laboratories, Bedford, MA) as per manufacturer’s instructions.
Cell Lines
We obtained Meg-01 and HEL cells from ATCC (Manassas, VA) where they are
authenticated before distribution. R. Baserga kindly provided HCT116-Dicer KO 2 cells
(Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA), and
we authenticated these cells for Dicer deficiency. We did not test cell lines for mycoplasma.
Measurement of Ca2+ mobilization
24 h before transfection, we plated Meg-01 cells (ATCC, Manassas, VA) at 1×106 cells
well−1 in 6-wells plates with RPMI 1640 media supplemented with 10% FBS without
antibiotics. We transfected cells with either human PCTP siRNA-SMART pool or non-
targeting siRNA control (ThermoFisher Scientific, Waltham, MA) by using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s instructions. We harvested cells 48
h after transfection and performed western-blot, qRT-PCR, and flow cytometry assays. For
monitoring Ca2+ mobilization under agonist stimulation, cells were washed, pre-incubated
with Fluo-4-AM (Invitrogen), recalcified and stimulated with 250 μM PAR4-AP or 50 μM
PAR1-AP54. We monitored changes in Meg-01 Ca2+ concentration over time using an
Accuri C6 flow cytometer.
Platelet mRNA profiling
We prepared leukocyte depleted platelets (LDP) RNA by density centrifugation and
immune-depletion of CD45+ cells as previously described, yielding less than 1
contaminating leukocyte in 5 million platelets13. We extracted RNA with TRIzol® (Life
Technologies, Carlsbad, CA). We minimized technical variation by use of the same highly-
trained technicians, same lots of reagents and same instruments throughout the duration of
the study. All RNA samples were subject to quality control screening using an Agilent
Bioanalyzer. We labeled 300 ng of LDP total RNA and hybridized it to the Human Gene 1.0
ST Array (Affymetrix, Santa Clara, CA). For mRNA data pre-processing, we used “apt-
probeset-summarize” from the Affymetrix Power Tools for background subtraction,
normalization and summarizing probeset values from Affymetrix Gene array. We adjusted
the background with the Robust-Multi-array average technique. We background corrected
the raw intensity values, log2 transformed and then quantile normalized them (the command
line option was “-a rma-sketch”) similar to our prior analysis55. Data deposited into NCBI
GeneExpressionOmnibus.
Platelet miRNA profiling
We performed digital miRNA profiling from 100 ng of LDP total RNA using the nCounter
human miRNA assay kit v1 (Nanostring Technologies, Seattle, WA) that counts miRNAs
without amplification and produces high sensitivity and specificity allowing accurate
comparisons of individual miRNA species within and between samples. In brief, a color-
coded reporter probe and a capture probe are hybridized, in solution to target molecules. The
captured molecules are then attached to a streptavidin-coated slide and then elongated and
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taligned via electrophoresis. Finally, the color-coded reporter probes are counted. This
technology has the advantage over standard microarray hybridization profiling of avoiding
the biasing effects of RNA amplification and of direct measurement of the number of
molecules detected and demonstrates linearity over 2.5 logs of concentration56. Total RNA
is hybridized in solution to reporter probes labeled with fluorescent bar codes. Via capture
probes, software counted the hybridized miRNAs adhered to a solid surface and the number
of bar codes. We determined expression levels of well characterized and validated human
(n=654) and human-associated viral miRNAs (n=80). To control for technical differences,
we normalized the data using spike-in positive controls. To account for loading differences
in miRNA content, we further normalized the data to total number of miRNA counts in each
sample. We set the background detection threshold as the average plus two standard
deviations of eight negative control probes. Notably, the values obtained in our data fell
within the linearity of the Nanostring assay. Data deposited into NCBI
GeneExpressionOmnibus.
Validation of RNA expression, and miRNA knockdown
We cultured the HCT-116-Dicer-KO cell line in McCoy’s 5A medium (Life Technologies,
Carlsbad, CA); and the Meg-01 and HEL cells in RPMI medium (Life Technologies)
adjusted to contain 10% (v/v) fetal bovine serum. We seeded cells 24 h before transfection
in 6-well plates without antibiotics. To validate miR-376c knock down of PCTP, we
transfected HCT115-Dicer-KO cells with 20–80 nM of pre-miR-376c or scrambled control
(Life Technologies). We transfected Meg-01 and HEL cell lines with 100 nM of pre-
miR-376c or scrambled control (Life Technologies), as well as hsa-miR-376c miRCURY
LNA™ microRNA inhibitor or miRCURY LNA™ microRNA Inhibitor Negative Control
(Exiqon, Denmark) using Lipofectamine LTX (Life Technologies) transfection agent
following the manufacturer’s protocol. After 6 h we replaced the media. We harvested the
HCT-116-Dicer-KO cells 6 h, 24 h and 48 h after transfection. We harvested Meg-01 and
HEL cell lines 48 h after transfection. We isolated total RNA using Trizol® Reagent
(Ambion). To validate relative expression levels of miRNAs and mRNAs, we performed
qRT-PCR of PCTP transcripts with the Power SYBR Green PCR master mix (Life
Technologies, Carlsbad, CA), using the following primers 5′-
AGAATGCAACGGAGAGACTGTGGT-3′, 5′-TCACATGGATCTTCCTCCCTTCCA-3′
and normalized to β-actin. We quantified mature hsa-miR-376c, hsa-miR-376b, hsa-
miR-410, hsa-miR-495 and let-7b levels using TaqMan® MicroRNA Reverse Transcription
Kit, TaqMan® MicroRNA assays together with TaqMan® Universal PCR Master Mix, No
AmpErase® UNG (Applied Biosystems). We used RNU6B expression to normalize miRNA
expression. We carried out real time PCR reaction and analyses in 384-well optical reaction
plates using the 7900HT instrument (Applied Biosystems).
Western blotting and antibodies
We lysed leukocyte-depleted platelets and homogenized them in 8 M urea buffer (8 M urea
in 10 mM Tris, pH 6.8, 1% SDS, 5 mM DTT in the presence of a 1x protein inhibitor mix
(Roche, Indianapolis, IN)). We separated extracts by 12% SDS–PAGE and transferred onto
PVDF membranes. We immunostained membranes with goat anti-human PC-TP57 and
mouse anti-human GAPDH monoclonal antibody58 (Santa Cruz Biotechnology, Dallas,
TX). We performed detection and densitometric analysis with Odyssey Infrared Imaging
System (Li-Cor, Lincoln, NE).
Hematopoietic Stem Cell (HSC) isolation and differentiation to megakaryocytes
We obtained cord blood from the New York Blood Center and diluted it 1:2 with PBS and
layered over Histopaque® (Sigma, St. Louis, MO). After 30 min centrifugation at 400 x g
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twe carefully collected the buffy coat. We isolated CD34+ cells using magnetic
immunoselection (Miltenyi Biotec, Auburn, CA) following the manufacture’s protocol. We
then cultured cells at 4×105 cells well−1 in a 24 well plate, with StemSpan™ media
(StemCell Technologies, Vancouver, Canada) supplemented with 25 ng mL−1 SCF and 20
ng mL−1 thrombopoietin (TPO; Peprotech, Rocky Hill, NJ). After 6 d we supplemented the
cultures with 50 ng mL−1 TPO only. Every 3 d, we harvested the cells, counted and re-
plated them at 4×105 cells well−1 in a 24 well plate with fresh media. We monitored
megakaryocytic differentiation by flow cytometry, testing for CD34, CD41 and CD42. At 16
d, we seeded cells onto a fibrinogen coated coverslip. We then stained cells with phalloidin-
alexa-533 (Life Technologies), rabbit anti-human tubulin59 and mouse anti-rabbit alexa-488
(Life Technologies). Then we mounted the coverslips on slides using ProLong® Gold
Antifade Reagent with DAPI (Life Technologies). Finally, we captured images using a Zeiss
LSM 510 Meta Confocal Laser Scanning Microscope with a META detector.
Statistical analysis
Before performing the study, we performed sample size calculations using a linear model
framework with Gaussian errors using effect sizes and variance estimates based on our
previous work where we performed genome wide expression profiling with purified platelet
samples 13,25. This effort indicated 150 subjects would provide greater than 85% power to
detect modeled associations between platelet agonist phenotypes and RNA expression
levels. For continuous phenotype (response) data in this study, we used qq-plots to evaluate
normality of errors about linear model fits. For binary count data, we employed binomial
sampling models, and used Fisher’s Exact tests to evaluate associations, such as when
testing the cross tabulation of those genes associated with PAR4 reactivity vs. those
associated with self-identified race. We did not find the variance of PAR4 reactivity within
each race to be significantly different by an F-test of the variances (F=1.4, 95% CI: 0.87–
2.15, P=0.2). We performed statistical analyses using the open source statistical
programming environment R60. We performed association analyses between platelet
phenotype PAR4 and gene expression using linear models. Multiple testing considerations
were made using the False Discovery Rate (FDR) methodology, and q-values were
estimated using the Benjamini-Hochberg method61 as made available through the R function
p. adjust.
Principle components analysis (PCA)—PCA is a commonly used mathematical
approach that allows an unbiased examination of population structure in large scale
genotype data. PCA transforms high dimensional multimarker genotypes encoded as
reference allele counts from many subjects into simple, low dimensional representations
through projection to additive combinations of allele counts where the weights are the PCA
loadings. This analysis permits identification of “structure” such as race in the data. We
applied this unbiased method to our samples. We extracted DNA from buffy coat
preparations from all PRAX1 subjects using the Gentra Puregene Blood Kit (Qiagen,
Netherlands). We hybridized DNA to the HumanOmni5 array (Illumnia Inc., San Diego,
CA) at the Laboratory for Translational Genomics at the Baylor College of Medicine. We
used the Eigenstrat software package62 to compute the PCA transformation excluding the
ethnicity information from the analysis.
Filters for detected and background probes—We excluded eight subjects for
presumed anti-platelet medication use (defined as arachidonic acid aggregation of <30%)
and one subject was excluded because of abnormal hematological parameters, leaving 154
samples for all subsequent analyses. In both the miRNA and mRNA data we used a two-step
filter to determine which probes to consider as expressed in our samples for the purposes of
downstream analyses. We first used the distribution of mean values for each probe across
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tsubjects to determine a cutoff that differentiated those features with background intensity
from others. We then counted the number of individual subjects with values that exceeded
this background cutoff. The count distribution for the number of subjects exceeding the
background cutoff was bimodal, indicating that most probes are either almost always
expressed or not in our cohort. To be considered commonly expressed, we therefore required
that at least 100 subjects express the miRNA above background and 115 subjects express the
mRNA above background. For the mRNAs we also required that the probeset was of
category ‘main’, as classified in HuGene-1_0-st-v1.na33.2.hg19.transcript.csv file (available
from www.affymetrix.com/support/technical/annotationfilesmain.affx). A sensitivity
analysis showed very little variation in the selected data based on small variations in the cut-
point for expressed RNAs, and the method was also robust to small variations in the
percentage cutoff for the number of people expressing each RNA.
Exploratory analyses—We performed exploratory cluster analyses on the miRNA
platelet expression data. We centered and hierarchically clustered using Cluster 3.0
normalized log2 transformed values of the 178 miRNAs above cutoff (original software by
Michael Eisen63, updated by Michiel de Hoon (University of Tokyo, http://bonsai.hgc.jp/
~mdehoon/software/cluster/software.htm)). We created a corresponding heatmap using Java
Treeview. We calculated Pearson correlation coefficients for all 178 miRNAs above cutoff
pairwise using the R statistical package.
Model based analyses—In addition to cluster analyses we performed a series of
correlative analyses to examine the association between RNA expression and subject
demographics, platelet agonist-induced aggregation and other hematologic parameters.
These analyses included simple and multiple linear regressions, performed in R using
analysis of variance (aov) tools that permit evaluation of multiple explanatory variables. In
the analysis of the PAR4 phenotype we treated PAR4 reactivity as the dependent variable
and included the demographic covariates and RNA expression data as explanatory. We took
a False Discovery approach to account for possible false positives in the mRNA expression
analysis, and we used the Benjamini-Hochberg linear step down method to control the
FDR14.
Network analysis—We constructed a network of miRNA-mRNA pairs using target
predictions and allowing an edge only if miRNA and mRNA levels met the following
criteria across the 154 subjects: 1) both the miRNA and mRNA are differentially expressed
by race, 2) both the mRNA and miRNA correlate with PAR4-mediated platelet reactivity, 3)
the miRNA is predicted to target the mRNA, 4) the RNA levels are inversely correlated with
one another, and 5) the miRNAs reside in the DLK1-DIO3 region. We then visualized the
miRNA-mRNA pairs using the Cytoscape software package.
Analysis of Racial SNV Allele Frequency and RNA expression probes—To
investigate the possibility that RNA expression differences observed between races could be
mediated by SNV variation in the probes in the two expression assays used – Affymetrix
Gene ST 1.0 and Nanostring – we performed additional analyses of our expression data
using information from the 1000 Genomes project Genomes Project Consortium (A map of
human genome variation from population-scale sequencing. Nature. 2010; 467: 1061–73.) as
a reference. We obtained data from the 1000 genomes website ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/supporting/, in particular the files:
AFR.2of4intersection_allele_freq.20100804.genotypes.vcf.gz
AFR.2of4intersection_allele_freq.20100804.genotypes.vcf.gz.tbi,
EUR.2of4intersection_allele_freq.20100804.genotypes.vcf.gz
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We then identified all 1 million+ probe sequence locations for probesets on the Affy
GeneST 1.0 array and the miRNAs comprising the Nanostring assay. We identified the
locations of all SNVs (SNPs) in the thousand genomes data that showed a significant
difference in allele frequency between races (EUR and AFR) based on Fisher’s exact test of
allele frequency and a Fisher’s Test p-value cutoff of 0.01, and we identified all those
expression probes that harbored a racially dimorphic SNP as defined by the Fisher’s test
criteria. We then performed analyses to consider their effect on our gene-level expression
and miRNA expression results. A boxplot of oligonucleotide probe level data for one of the
probesets bearing a probe with a racially dimorphic SNP is presented in Supplementary
Figure 3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
Racial difference in PAR4-mediated platelet aggregation. (a) Mean ± SEM of maximal %
aggregation of 70 black and 84 white PRP samples measured by light transmission
aggregometry following stimulation with 500 μg ml−1 arachidonic acid (AA), 4 μM ADP,
anti-CD9 (500, 750 or 2000 ng ml−1), collagen-related peptide (CRP, 10 or 20 ng ml−1),
PAR1-AP (1.0 or 2.5 μM), or PAR4-AP (50 or 75 μM PAR4-AP). *, P < 0.0001, 2-sided
Mann-Whitney for maximal % aggregation. Race was the dominant determinant of the
PAR4 ARS when we considered the racial differences in age, gender, body mass index
(BMI) and platelet count (P=5.15×10−8, ANOVA partial F statistic of race for PAR ARS,
normality of residuals checked by qq-plot). (b) Time to 50% aggregation of washed platelets
from black (n=5) and white (n=5) subjects after thrombin activation through PAR4 in the
presence of 20 μM of the PAR1-specific antagonist, BMS-200261. P=3.56×10−5, partial F
statistic for race effect using 2-way ANOVA (concentration, race). Insert demonstrates
ability of 20 μM BMS to block maximally stimulated PAR1- but not PAR4-induced platelet
aggregation. (c) PCA of 2 million genome wide genotype markers demonstrated two groups
of PRAX1 subjects that strongly correlated with self-identified race and ethnicity.
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Racial differences in human platelet PC-TP expression and function. (a) Mean PCTP
mRNA levels are higher in 70 blacks than 84 whites (P=1×10−23, 2-sided t-test). (b) PCR
validation of PCTP mRNA. Correlation between microarray and qRT-PCR data using linear
regression (SPSS15.0 software). The regression line with its 95% confidence intervals is
shown (P<0.0001, Pearson correlation, Fisher’s z transform). (c) Representative western
blots showing higher PC-TP levels in platelets from 8 blacks than 8 whites. PC-TP and
GAPDH antibodies probed filters that were transferred from the same gel. Image cropped
for clarity. (d) Summary of western blot quantification of platelet PC-TP from 70 blacks and
82 whites (P=3.8×10−6, 2 sided t-test). All samples are derived from the same experiment
and processed in parallel. (e) Western blot of mouse platelet Pctp with controls. Image
cropped for clarity. (f) Representative aggregometry tracings of platelets in stimulated with
PAR1-AP (left) or PAR4-AP (center) with differing concentrations of the PC-TP inhibitor,
A1. The bar graph (right) summarizes studies from 3 subjects (2W, 1 B). Compound A1
blocked platelet aggregation to PAR4-AP but not PAR1-AP (P=0.016, 2-sided t-test). Color
key for panels f-h shown in panel f. (g) Calcium mobilization in the megakaryocytic cell
line, Meg-01 transfected cells with a control siRNA or an siRNA against PCTP after no
agonist or stimulation with PAR1-AP (left) or PAR4-AP (right). Curves represent mean ±
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tSEM of three separate experiments for PAR1-AP and four different experiments for
PAR4-4P. *, (P=0.013, 2-sided t-test) for the maximum fold change between siRNA-PCTP
vs. si-control. (h) Immunoblot of Meg-01 cells transfected with non-targeting siRNA control
(si-ctrl) or human PCTP siRNA-SMART pool (si-PCTP). (i) Effect of race on PAR4-AP-
mediated platelet calcium mobilization (P=0.02, 2-way ANOVA).
Edelstein et al. Page 19
Nat Med. Author manuscript; available in PMC 2014 June 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3.
Relationships among racial differences in PAR4 phenotype and transcripts. (a) Racial
differences between 70 blacks and 84 whites for PAR4 reactivity, mRNAs and miRNAs are
presented in 3 heatmaps. Each column represents data from the same individual. Rows
represent 93 mRNAs (in middle panel) and 18 miRNAs (lower panel) that are DE by race
and correlated with PAR4 reactivity. Vertical red bar indicates strongly correlated DLK1-
DIO3 region miRNAs. (b) Network of miRNA-mRNA pairs that are differentially expressed
by race and PAR4-mediated platelet aggregation.
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tFigure 4.
MiR-376c regulates PCTP expression in megakaryocytes. (a) Transfection of miR-376c
diminishes PC-TP protein expression in Dicer-low HCT cells. *, P<0.05. (b) Transfection of
miR-376c diminishes PC-TP protein expression in the megakaryocytic cell line, Meg-01. (c)
Transfection of miR-376c locked nucleic acid (LNA) inhibitor increased PCTP mRNA
levels, while overexpression of the miR-376c precursor decreased PCTP mRNA in
megakaryocytic cell lines, Meg-01 and HEL cells. P-value calculation is T-test relative to
appropriate scrambled control. Levels were normalized to β-actin. (d) Demonstration of
human CD34+ hematopoietic stem cell derived megakaryocytes. Flow cytometric analysis of
CD34+ cells cultured for 4 and 12 d and stained for megakaryocyte-specific markers CD41
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tand CD42. (e) 14 d megakaryocytes showing proplatelet formation with DNA (DAPI,
purple-blue), α-tubulin (green) and actin (red) staining. (f) qRT-PCR quantification of PCTP
in 14 d CD61+ 14 d megakaryocytes, transfected with miR-376c locked nucleic acid (LNA)
inhibitor or pre-miR-376. Levels were normalized to β-actin. (g) Activity of a luciferase
reporter with the 3′UTR of PCTP with a wild type (WT PCTP) or mutated miR-376c
(ΔPCTP) target site. Only the WT construct was knocked down when co-transfected with
miR-376 precursor. Levels were normalized with a β-gal control.
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tFigure 5.
A large miRNA cluster in the DLK1-DIO3 region is differentially expressed by race. (a)
Heatmap of Pearson’s correlation coefficients amongst all combinations of pairs of the 178
commonly expressed platelet miRNAs. (b) The approximate locations of the 54 miRNAs in
the DLK1-DIO3 region. Color coding indicates which miRNA genes had at least one mature
miRNA product detected above or below the arbitrary threshold of commonly expressed
miRNAs and the four miRNA genes that were not queried. Figure not to scale. (c) Each dot
represents the average expression of one of the 24 DLK1-DIO3 region miRNAs above
cutoff. Using a binomial model, the chance that all 24 of the expressed DLK1-DIO3
miRNAs would be higher in whites is 1.2 × 10−24 based on a genome-wide (excluding the
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tDLK1-DIO3 region) rate of 51.4% of DE miRNAs higher in whites. (d) A schematic
summarizing the relationship of race with the expression of the DLK1-DIO3 region miRNAs
and target mRNAs and PAR4 reactivity.
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Table 1
miR-376c levels correlated against PCTP mRNA levels, PC-TP protein levels, and PAR4 reactivity in all 154
PRAX1 samples.
Correlation with miR-376c levels
Pearson r (P-value)
PCTP mRNA −0.214(0.008)
PC-TP protein −0.211(0.009)
Platelet PAR4 reactivity −0.161(0.049)
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